Cargando…
SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days
Background: While the metabolic effects of testosterone have been well studied, the effects of co-administration of an androgen and progestin are less established. Two novel compounds being investigated for male hormonal contraception, dimethandrolone undecanoate (DMAU) and 11β-methyl-19-nortestoste...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209035/ http://dx.doi.org/10.1210/jendso/bvaa046.1939 |
_version_ | 1783530986342973440 |
---|---|
author | Yuen, Fiona Thirumalai, Arthi Swerdloff, Ronald S Liu, Peter Y Pak, Youngju Hull, Laura Page, Stephanie T Wang, Christina |
author_facet | Yuen, Fiona Thirumalai, Arthi Swerdloff, Ronald S Liu, Peter Y Pak, Youngju Hull, Laura Page, Stephanie T Wang, Christina |
author_sort | Yuen, Fiona |
collection | PubMed |
description | Background: While the metabolic effects of testosterone have been well studied, the effects of co-administration of an androgen and progestin are less established. Two novel compounds being investigated for male hormonal contraception, dimethandrolone undecanoate (DMAU) and 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), have both androgenic and progestational activity. Aim: Characterize the effects of DMAU and 11β-MNTDC on metabolic parameters including weight, lipid parameters, insulin resistance, and adiponectin. Methods: Two randomized, double-blind, placebo-controlled studies in healthy men were previously performed to assess the safety and tolerability of DMAU and 11β-MNTDC taken orally for 28 days. Insulin and adiponectin assays were performed on a subset of banked samples. Changes in weight, LDL-C, HDL-C, fasting glucose, HOMA-IR, and adiponectin were assessed. Two way ANOVA with post hoc Tukey HSD was performed to assess for dosage (0, 200, or 400mg) and drug (DMAU or 11β-MNTDC) effects. Results: A total of 85 subjects were included in this secondary analysis. There was a statistically significant decrease in HDL-C (mean change -11 and -15 mg/dL) and increase in weight (3 and 2 kg) and LDL-C (18 and 23 mg/dL) in the DMAU and 11β-MNTDC 400mg groups respectively. There was no significant difference between the 200 and 400 mg groups nor differences between the two androgens. There were no statistically significant changes in fasting glucose, adiponectin or HOMA-IR. Conclusion: There were mild changes in weight, HDL-C, and LDL-C after 28 days of DMAU and 11β-MNTDC without significant changes in markers of insulin resistance or differences between the two compounds. Changes in metabolic parameters should be monitored and considered during further development of compounds for male hormonal contraception. |
format | Online Article Text |
id | pubmed-7209035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72090352020-05-13 SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days Yuen, Fiona Thirumalai, Arthi Swerdloff, Ronald S Liu, Peter Y Pak, Youngju Hull, Laura Page, Stephanie T Wang, Christina J Endocr Soc Reproductive Endocrinology Background: While the metabolic effects of testosterone have been well studied, the effects of co-administration of an androgen and progestin are less established. Two novel compounds being investigated for male hormonal contraception, dimethandrolone undecanoate (DMAU) and 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), have both androgenic and progestational activity. Aim: Characterize the effects of DMAU and 11β-MNTDC on metabolic parameters including weight, lipid parameters, insulin resistance, and adiponectin. Methods: Two randomized, double-blind, placebo-controlled studies in healthy men were previously performed to assess the safety and tolerability of DMAU and 11β-MNTDC taken orally for 28 days. Insulin and adiponectin assays were performed on a subset of banked samples. Changes in weight, LDL-C, HDL-C, fasting glucose, HOMA-IR, and adiponectin were assessed. Two way ANOVA with post hoc Tukey HSD was performed to assess for dosage (0, 200, or 400mg) and drug (DMAU or 11β-MNTDC) effects. Results: A total of 85 subjects were included in this secondary analysis. There was a statistically significant decrease in HDL-C (mean change -11 and -15 mg/dL) and increase in weight (3 and 2 kg) and LDL-C (18 and 23 mg/dL) in the DMAU and 11β-MNTDC 400mg groups respectively. There was no significant difference between the 200 and 400 mg groups nor differences between the two androgens. There were no statistically significant changes in fasting glucose, adiponectin or HOMA-IR. Conclusion: There were mild changes in weight, HDL-C, and LDL-C after 28 days of DMAU and 11β-MNTDC without significant changes in markers of insulin resistance or differences between the two compounds. Changes in metabolic parameters should be monitored and considered during further development of compounds for male hormonal contraception. Oxford University Press 2020-05-08 /pmc/articles/PMC7209035/ http://dx.doi.org/10.1210/jendso/bvaa046.1939 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Reproductive Endocrinology Yuen, Fiona Thirumalai, Arthi Swerdloff, Ronald S Liu, Peter Y Pak, Youngju Hull, Laura Page, Stephanie T Wang, Christina SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days |
title | SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days |
title_full | SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days |
title_fullStr | SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days |
title_full_unstemmed | SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days |
title_short | SAT-040 Changes in Metabolic Parameters After Administration of Novel Oral Androgens with Progestational Activity for 28 Days |
title_sort | sat-040 changes in metabolic parameters after administration of novel oral androgens with progestational activity for 28 days |
topic | Reproductive Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209035/ http://dx.doi.org/10.1210/jendso/bvaa046.1939 |
work_keys_str_mv | AT yuenfiona sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days AT thirumalaiarthi sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days AT swerdloffronalds sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days AT liupetery sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days AT pakyoungju sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days AT hulllaura sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days AT pagestephaniet sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days AT wangchristina sat040changesinmetabolicparametersafteradministrationofnoveloralandrogenswithprogestationalactivityfor28days |